Hepatitis C Virus Clearance by Direct-Acting Antivirals Agents Improves Endothelial Dysfunction and Subclinical Atherosclerosis: HEPCAR Study

• Published in: Clinical and translational gastroenterology Vol. 11; no. 8; p. e00203
• Main Authors: Muñoz-Hernández, Rocío, Ampuero, Javier, Millán, Raquel, Gil-Gómez, Antonio, Rojas, Ángela, Macher, Hada C., Gallego-Durán, Rocío, Gato, Sheila, Montero-Vallejo, Rocío, Rico, María C., Maya-Miles, Douglas, Sánchez-Torrijos, Yolanda, Soria, Isabel Carmona, Stiefel, Pablo, Romero-Gómez, Manuel
• Format: Journal Article
• Language: English
• Published: United States Wolters Kluwer 01.08.2020; Wolters Kluwer Health Medical Research, Lippincott Williams & Wilkins
• Subjects: Atherosclerosis; Biomarkers; Blood platelets; Cardiovascular disease; Cholesterol; Heart attacks; Hepatitis C; Hypertension; Infections; Inflammation; Insulin resistance; Lipoproteins; Liver; Liver cancer; Liver diseases; Metabolism; Normal distribution; Oxidative stress; Risk factors; Software; Vascular endothelial growth factor; Viral infections
• DOI: 10.14309/ctg.0000000000000203
• ISSN: 2155-384X

Hepatitis C virus (HCV) infection has been related to increased cardiovascular (CV) risk. The aim of this study was to analyze the impact of sustained virological response (SVR) on endothelial dysfunction and subclinical atherosclerosis in patients with hepatitis C virus treated with direct-acting antiviral agents. A total of 114 patients were prospectively recruited and underwent CV risk assessment including (i) endothelial dysfunction determined through laser Doppler flowmetry and (ii) subclinical atherosclerosis, elucidated by the ankle-brachial index (ABI). Atherogenic lipid profile (total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglycerides); markers of oxidative stress (oxidized low-density lipoprotein antibodies [OLAbs]), soluble markers of adhesion (vascular cell adhesion molecule [VCAM], e-selectin, and soluble markers of angiogenesis; and vascular endothelial growth factor, endothelial [EMPs] and platelet [PMPs] apoptotic microparticles, and cell-free DNA [cfDNA]) were measured. All determinations were performed at baseline, 12 weeks (SVR time), and 1 year after treatment. In patients with endothelial dysfunction, area of hyperemia improved after virus clearance (P = 0.013) and was related to significant decrease in VCAM, e-selectin (P < 0.001), and cfDNA (P = 0.017) and to increased OLAb levels (P = 0.001). In patients with subclinical atherosclerosis at baseline, a significantly improved ABI was seen after HCV clearance (P < 0.001). Levels of both EMPs and PMPs also decreased after SVR and at follow-up (P = 0.006 and P = 0.002, respectively). HCV clearance improved not only liver function but also endothelial dysfunction and subclinical atherosclerosis promoted by decrease in levels of VCAM, e-selectin, cfDNA, and PMPs and EMPs.